TRAVERE THERAPEUTICS, INC. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
TRAVERE THERAPEUTICS, INC. (TVTX) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of -$33.47 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2024-12-31 was $139.12M, a 36223.50% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2024-09-30 was $46.00K.
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2024-06-30 was $782.00K, a 69.03% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2024-03-31 was -$525.00K, a 100.24% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2025 was -$33.47M, a 124.00% decline from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2024 was $139.42M, a 36.66% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2023 was $220.13M, a 83.37% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2022 was $120.05M, a 49.51% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$33.47M 10-K · filed 2026-02-19 | ||||||
| 2024-12-31 | $139.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $139.16M derived: sum of 2 quarters · filed 2026-02-19 | $139.95M derived: sum of 3 quarters · filed 2026-02-19 | $139.42M 10-K · filed 2026-02-19 | |||
| 2024-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $828.00K derived: sum of 2 quarters · filed 2024-10-31 | $303.00K 10-Q · filed 2024-10-31 | $686.00K derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2024-06-30 | $782.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $257.00K 10-Q · filed 2024-08-01 | $640.00K derived: sum of 3 quarters · filed 2026-02-19 | $266.00K derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2024-03-31 | -$525.00K 10-Q · filed 2024-05-06 | -$142.00K derived: sum of 2 quarters · filed 2026-02-19 | -$516.00K derived: sum of 3 quarters · filed 2026-02-19 | $2.01M derived: sum of 4 quarters · filed 2026-02-19 | |||
| 2023-12-31 | $383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $9.00K derived: sum of 2 quarters · filed 2026-02-19 | $2.53M derived: sum of 3 quarters · filed 2026-02-19 | $220.13M 10-K · filed 2026-02-19 | |||
| 2023-09-30 | -$374.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.15M derived: sum of 2 quarters · filed 2024-10-31 | $219.75M 10-Q · filed 2024-10-31 | $220.91M derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $220.13M 10-Q · filed 2024-08-01 | $221.28M derived: sum of 3 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $217.60M 10-Q · filed 2024-05-06 | $218.75M derived: sum of 2 quarters · filed 2025-02-21 | |||||
| 2022-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $120.05M 10-K · filed 2025-02-21 | |||||
| 2022-09-30 | $118.90M 10-Q · filed 2023-11-07 | ||||||
| 2021-12-31 | $237.79M 10-K · filed 2024-02-20 | ||||||
| 2018-03-31 | -$2.70M 10-Q · filed 2018-07-06 | ||||||
| 2017-09-30 | $5.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.94M derived: sum of 2 quarters · filed 2017-11-07 | $4.08M 10-Q · filed 2017-11-07 | ||||
| 2017-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$1.75M 10-Q · filed 2017-08-09 | |||||
| 2017-03-31 | $146.00K 10-Q · filed 2018-07-06 | -$361.00K 10-Q · filed 2017-05-05 | |||||
| 2016-09-30 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $2.12M derived: sum of 2 quarters · filed 2017-11-07 | $1.20M 10-Q · filed 2017-11-07 | ||||
| 2016-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$2.84M 10-Q · filed 2017-08-09 | |||||
| 2016-03-31 | -$926.00K 10-Q · filed 2017-05-05 | ||||||
| 2015-09-30 | -$40.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$39.01M derived: sum of 2 quarters · filed 2016-11-04 | $100.37M 10-Q · filed 2016-11-04 | $100.54M 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $140.48M 10-Q · filed 2016-08-05 | $140.24M 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $139.38M 10-Q · filed 2016-05-05 | $139.17M 10-Q · filed 2015-05-11 | |||||
| 2014-09-30 | $3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $57.24M derived: sum of 2 quarters · filed 2015-11-06 | $95.85M 10-Q · filed 2015-11-06 | $95.85M 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $53.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $92.31M 10-Q · filed 2015-08-10 | |||||
| 2014-03-31 | $38.62M 10-Q · filed 2015-05-11 | ||||||
| 2013-09-30 | $29.51M 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |